東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Unhealthy pharmaceutical regulation ...

Abraham, John, (1961-)

FindBook

Google Book

Amazon

博客來

Unhealthy pharmaceutical regulation : = innovation, politics and promissory science /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Unhealthy pharmaceutical regulation :/ Courtney Davis, Kings College London, UK and John Abraham, University of Sussex, UK.
其他題名:	innovation, politics and promissory science /
作者:	Abraham, John,
其他作者:	Davis, Courtney,
面頁冊數:	1 online resource.
內容註:	Putting Pharmaceutical Regulation to the Test: A Social Science for Public Health -- The Political Economy of 'Innovative' Drug Regulation in the Neo-Liberal Era -- Designs on Diabetes Drugs -- Desperate Regulation for Desperate Cancer Patients -- The Making of a Harmful 'Therapeutic Breakthrough' -- The Regulatory Science and Politics of Risk Management -- Conclusions and Policy Implications.
標題:	Drugs - Law and legislation - European Union countries. -
電子資源:	http://link.springer.com/10.1057/9781137349477
ISBN:	1137349476 (electronic bk.)

Unhealthy pharmaceutical regulation : = innovation, politics and promissory science /
Abraham, John,1961-

Unhealthy pharmaceutical regulation :innovation, politics and promissory science /Courtney Davis, Kings College London, UK and John Abraham, University of Sussex, UK. - 1 online resource.

Includes bibliographical references and index.

Putting Pharmaceutical Regulation to the Test: A Social Science for Public Health -- The Political Economy of 'Innovative' Drug Regulation in the Neo-Liberal Era -- Designs on Diabetes Drugs -- Desperate Regulation for Desperate Cancer Patients -- The Making of a Harmful 'Therapeutic Breakthrough' -- The Regulatory Science and Politics of Risk Management -- Conclusions and Policy Implications.

"European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health. "--

ISBN: 1137349476 (electronic bk.)

Source: 518163Palgrave Macmillanhttp://www.palgraveconnect.comSubjects--Topical Terms:

836810
Drugs
--Law and legislation--European Union countries.Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RA401.A1 / A27 2013

Dewey Class. No.: 362.17/82

Unhealthy pharmaceutical regulation : = innovation, politics and promissory science /
LDR:03165cmm a2200397Ki 4500 001 1949920
003 OCoLC
005 20140910115744.0
006 m o d
007 cr cnu---unuuu
008 231227s2013 nyu ob 001 0 eng d
020 $a 1137349476 (electronic bk.)
020 $a 9781137349477 (electronic bk.)
029 1 $a NLGGC $b 371078407
035 $a (OCoLC)863036824
035 $a ocn863036824
035 $a 1949920
037 $a 518163 $b Palgrave Macmillan $n http://www.palgraveconnect.com
040 $a UKPGM $b eng $e rda $e pn $c UKPGM $d OCLCO $d IDEBK $d CDX $d N$T $d YDXCP $d E7B $d OCLCO
043 $a n-us--- $a e------
049 $a TEFA
050 4 $a RA401.A1 $b A27 2013
072 7 $a POL $x 019000 $2 bisacsh
072 7 $a POL $x 027000 $2 bisacsh
082 0 4 $a 362.17/82 $2 23
100 1 $a Abraham, John, $d 1961- $e author. $3 3648061
245 1 0 $a Unhealthy pharmaceutical regulation : $b innovation, politics and promissory science / $c Courtney Davis, Kings College London, UK and John Abraham, University of Sussex, UK.
264 1 $a New York, NY : $b Palgrave Macmillan, $c 2013.
300 $a 1 online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
504 $a Includes bibliographical references and index.
505 0 $a Putting Pharmaceutical Regulation to the Test: A Social Science for Public Health -- The Political Economy of 'Innovative' Drug Regulation in the Neo-Liberal Era -- Designs on Diabetes Drugs -- Desperate Regulation for Desperate Cancer Patients -- The Making of a Harmful 'Therapeutic Breakthrough' -- The Regulatory Science and Politics of Risk Management -- Conclusions and Policy Implications.
520 $a "European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health. "-- $c Provided by publisher.
588 $a Description based on print version record.
650 0 $a Drugs $x Law and legislation $z European Union countries. $3 836810
650 0 $a Drugs $x Law and legislation $z United States. $3 746824
650 0 $a Pharmaceutical industry $x Political aspects. $3 2076617
650 0 $a Pharmaceutical policy $z European Union countries. $3 836811
650 0 $a Pharmaceutical policy $z United States. $3 746826
650 7 $a MEDICAL / Health Policy. $2 bisacsh $3 2076618
650 7 $a MEDICAL / Pharmacy. $2 bisacsh $3 2076619
650 7 $a POLITICAL SCIENCE / Public Policy / General. $2 bisacsh $3 1598265
650 7 $a POLITICAL SCIENCE / Public Policy / Social Security $2 bisacsh $3 1599296
650 7 $a POLITICAL SCIENCE / Public Policy / Social Services & Welfare $2 bisacsh $3 1599297
650 7 $a SOCIAL SCIENCE / Disease & Health Issues. $2 bisacsh $3 1598577
650 7 $a SOCIAL SCIENCE / Sociology / General. $2 bisacsh $3 1529205
655 4 $a Electronic books. $2 lcsh $3 542853
700 1 $a Davis, Courtney, $d 1965- $e author. $3 3648062
776 0 8 $i Print version: $a Abraham, John, 1961- author. $t Unhealthy pharmaceutical regulation $z 9780230008663 $w (DLC) 2013021799 $w (OCoLC)144227252
856 4 0 $3 Palgrave Connect $u http://link.springer.com/10.1057/9781137349477